TWI871406B - 含西羅莫司(sirolimus)或其鹽之水性懸浮組合物 - Google Patents

含西羅莫司(sirolimus)或其鹽之水性懸浮組合物 Download PDF

Info

Publication number
TWI871406B
TWI871406B TW109146288A TW109146288A TWI871406B TW I871406 B TWI871406 B TW I871406B TW 109146288 A TW109146288 A TW 109146288A TW 109146288 A TW109146288 A TW 109146288A TW I871406 B TWI871406 B TW I871406B
Authority
TW
Taiwan
Prior art keywords
aqueous suspension
suspension composition
sirolimus
composition
polyoxyethylene
Prior art date
Application number
TW109146288A
Other languages
English (en)
Chinese (zh)
Other versions
TW202135806A (zh
Inventor
藤澤豊実
芥川礼華
Original Assignee
日商參天製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商參天製藥股份有限公司 filed Critical 日商參天製藥股份有限公司
Publication of TW202135806A publication Critical patent/TW202135806A/zh
Application granted granted Critical
Publication of TWI871406B publication Critical patent/TWI871406B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109146288A 2019-12-26 2020-12-25 含西羅莫司(sirolimus)或其鹽之水性懸浮組合物 TWI871406B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019237226 2019-12-26
JP2019-237226 2019-12-26

Publications (2)

Publication Number Publication Date
TW202135806A TW202135806A (zh) 2021-10-01
TWI871406B true TWI871406B (zh) 2025-02-01

Family

ID=76575568

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109146288A TWI871406B (zh) 2019-12-26 2020-12-25 含西羅莫司(sirolimus)或其鹽之水性懸浮組合物

Country Status (9)

Country Link
US (1) US20230055121A1 (https=)
EP (1) EP4082544A4 (https=)
JP (2) JP7682103B2 (https=)
KR (1) KR20220122612A (https=)
CN (2) CN118340726A (https=)
AU (1) AU2020411442B2 (https=)
CA (1) CA3162626A1 (https=)
TW (1) TWI871406B (https=)
WO (1) WO2021132565A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942607A (zh) * 2023-01-13 2023-10-27 杭州微致生物科技有限公司 一种西罗莫司混悬液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334734A (zh) * 2017-07-10 2017-11-10 浙江大学 一种西罗莫司或其衍生物的眼用制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2507078T3 (es) * 2007-08-16 2014-10-14 Santen Pharmaceutical Co., Ltd Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
CN105073112B (zh) 2013-03-13 2017-12-29 参天制药株式会社 睑板腺功能障碍的治疗剂
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
CN105833344B (zh) * 2016-04-26 2019-04-26 青岛慧生惠众生物科技有限公司 一种可注射水凝胶在制备眼内填充物中的应用
CN106420607B (zh) 2016-11-02 2019-06-28 北京诺康达医药科技股份有限公司 一种西罗莫司纳米混悬剂及其制备方法
EP3565520B1 (en) * 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
US20200261427A1 (en) * 2019-02-20 2020-08-20 Al Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334734A (zh) * 2017-07-10 2017-11-10 浙江大学 一种西罗莫司或其衍生物的眼用制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 , G BUECH, et al., "Formulation of sirolimus eye drops and corneal permeation studies", Journal of Ocular Pharmacology and Therapeutics, 23(3), Mary Ann Liebert, Inc., 2007: 292~303. *

Also Published As

Publication number Publication date
WO2021132565A1 (ja) 2021-07-01
AU2020411442B2 (en) 2026-02-12
KR20220122612A (ko) 2022-09-02
JP7682103B2 (ja) 2025-05-23
CA3162626A1 (en) 2021-07-01
AU2020411442A1 (en) 2022-06-23
JPWO2021132565A1 (https=) 2021-07-01
US20230055121A1 (en) 2023-02-23
CN118340726A (zh) 2024-07-16
EP4082544A4 (en) 2024-01-10
JP2025111828A (ja) 2025-07-30
TW202135806A (zh) 2021-10-01
CN114845714A (zh) 2022-08-02
CN114845714B (zh) 2024-05-14
EP4082544A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
KR102525438B1 (ko) 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
JP6487452B2 (ja) ブリンゾラミドを含む医薬組成物
EA034839B1 (ru) Офтальмологический раствор
US20240390515A1 (en) Multidose ophthalmic compositions
JP2024161426A (ja) 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの結晶形態及びその製剤
TWI871406B (zh) 含西羅莫司(sirolimus)或其鹽之水性懸浮組合物
KR20160060656A (ko) 폴리에틸렌글리콜 함유 조성물
CN108601763A (zh) 含有多佐胺和溴莫尼定的药物组合物
WO2010119942A1 (ja) レボカバスチン懸濁型点眼剤
AU2021260669B2 (en) A formulation for treating ophthalmic conditions
CA2296562A1 (en) Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
RU2842860C1 (ru) Водная суспензионная композиция, содержащая сиролимус или его соль
TWI773778B (zh) 含有水溶性黏稠化劑之醫藥組合物
KR20230107624A (ko) 레보플록사신 및 케토롤락을 함유하는 안과용 조성물, 이의 제조 방법 및 용도
HK40080964B (zh) 用於治疗眼部状况的制剂
KR20170129832A (ko) 폴리펩티드를 함유하는 의약 조성물
EA051764B1 (ru) Офтальмологическая композиция, содержащая левофлоксацин и кеторолак, способ ее получения и ее применение
NZ619229B2 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
NZ619229A (en) Topical ophthalmological pharmaceutical composition containing regorafenib